"Miriam E. Tucker
Medscape Medical News
The US Food and Drug Administration has approved the empagliflozin/linagliptin combination Glyxambi (Boehringer Ingelheim/Eli Lilly) as adjunctive treatment to diet and "...
There were no reports of overdose during the clinical development program for FARXIGA.
In the event of an overdose, contact the Poison Control Center. It is also reasonable to employ supportive measures, as dictated by the patient's clinical status. The removal of dapagliflozin by hemodialysis has not been studied.
- History of a serious hypersensitivity reaction to FARXIGA [see ADVERSE REACTIONS].
- Severe renal impairment, end-stage renal disease (ESRD), or patients on dialysis [see Use In Specific Populations].
Last reviewed on RxList: 3/27/2015
This monograph has been modified to include the generic and brand name in many instances.
Additional Farxiga Information
Report Problems to the Food and Drug Administration
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.
Find out what women really need.